REGENERX BIOPHARMACEUTICALS INC (RGRX) [Rocket]

Date Filed	Type	Description
12/09/2010	BW	RegeneRx Receives Mexican Patent for the Use of TB4 for Prevention and Treatment of Cardiac Damage
12/01/2010	BW	RegeneRx Receives Australian Patent Using TB4 to Protect Against Biological, Chemical and Toxic Agents
11/30/2010	BW	Researchers Identify Potential Thymosin Beta 4 Receptor
11/17/2010	BW	RegeneRx Receives Australian Patent Using Tß4 for Treatment Of Gastrointestinal Disorders
11/16/2010	BW	RegeneRx President and CEO to Present at Maxim Group Growth Conference
11/02/2010	BW	RegeneRx Reports Positive Results of Preclinical Dry Eye Study
11/01/2010	BW	RegeneRx Receives Non-compliance Notice from NYSE Amex; Intends to Request Hearing
10/26/2010	BW	RegeneRx Announces Letter to Stockholders Posted on Website
09/02/2010	BW	RegeneRx Appoints R. Don Elsey to Board of Directors
07/19/2010	BW	Researchers Report in Neuroscience that TB4 Improves Neurological Function after Stroke
07/08/2010	BW	RegeneRx Awarded Australian Patent for New TB4 Applications
06/03/2010	BW	Henry Ford Study: Synthetic Peptide May Regenerate Brain Tissue in Stroke Victims
06/02/2010	BW	RegeneRx Announces Exercise of Over-Allotment Option for Recent Public Offering
05/18/2010	BW	RegeneRx Announces Pricing of Public Offering
05/14/2010	BW	First Human Data on RegeneRx's Drug Candidate RGN-259 Published in Archives of Ophthalmology
05/13/2010	BW	RegeneRx Awarded $3 Million Grant from National Institutes of Health for Development of Heart Attack Drug
04/16/2010	BW	RegeneRx Biopharmaceuticals Announces Proposed Public Offering
04/08/2010	BW	New Tß4 Eye Data to be Presented at ARVO Meeting
03/05/2010	BW	Researchers Report that Thymosin beta 4 Improves Neurological Function after Stroke
03/02/2010	BW	RegeneRx Biopharmaceuticals' President and CEO to Present at 22nd Annual Roth Capital Growth Stock Conference
02/26/2010	BW	Researchers Report Novel Biological Properties of Fragments of Thymosin Beta 4